admin

Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the closing of its initial public offering of 7,187,500 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 937,500 additional shares of common stock, at a public offering price of $17.00 per share.  The gross proceeds to Principia, before deducting underwriting discounts and commissions and offering expenses, were approximately $122.2 million.  All of the common stock was offered by Principia. Principia’s common stock is listed on The Nasdaq Global Select Market under the trading symbol “PRNB.”

Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus, with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management LLC. Existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures also participated. In addition, Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, Managing Director at Clarus, will join Galera’s Board of Directors.

The Maryland Tech Council (MTC), the state’s largest trade association supporting the technology and life sciences sectors, today announced the appointment of Marty Rosendale as Chief Executive Officer (CEO), effective immediately.

Host:  UM BioPark & Wexford Science + Technology

Location:  UMB BioPark On the Nook Cafe Patio 801 W. Baltimore Street Baltimore  Maryland  21201

Time:  5:00pm to 6:30pm

Mingle with our honored guest, Alex Triantis, Dean of the Robert H. Smith School of Business, other members of the Smith School community, BioPark tenants, and UMB faculty & staff

Join one of the 24 Institutes and Centers within the NIH that awards extramural grants! Extramural grants account for approximately 80 percent of NIH’s budget and are awarded to investigators at more than 2,500 universities, medical schools, and other research organizations around the world. To learn more about the grants process, types of grant programs, and the peer review process, visit the website for the Office of Extramural Research.

It’s the 21st century and information is just right at the tip of our fingers – thanks to the wide, wide, internet world. However, in spite of all the availability of information and the easy access to it, many people are still under the cloak of hoaxes and myths – and the business world is no exemption.

Another year, another list of the Top U.S. Cities for Global Trade. If there’s one thing that strikes us about this list over the past couple of years is that the reach of the global economy has not just stretched to other shores but into virtually every city in the United States, no matter the size.

MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, today announced that AblaCare, CroiValve, FineHeart, Sana Health, and Spect have been selected as finalists to compete for the title of MedTech Innovator of 2018, out of over 700 applicants. The Grand Prize winner of $350,000 will be determined by the vote of the audience at the largest gathering of medtech industry leaders in North America on Sept. 25 in Philadelphia, PA at The MedTech Conference, powered by AdvaMed.

Johnson & Johnson Innovation’s Manhattan outpost of its startup incubator, JLabs, is the new kid on the NYC-health-tech block.

Expanding its portfolio of innovative health solutions, the Inova Personalized Health Accelerator (IPHA) has invested in a new therapy company that is developing a solution to address a major unmet need in patients with olfactory impairment. Sense of smell can often be taken for granted, until it is lost. This occurs most commonly by sino-nasal disease and upper respiratory infection, and in many cases, by head trauma. Cyrano Therapeutics understands the profound impact these senses can have on quality of life and is developing the first safe and effective nasal spray to restore and maintain the sense of smell and its connection with the ability to detect flavor in food (often perceived as taste). According to the peer-reviewed journal BMC Ear, Nose and Throat Disorders, 14 million patients in the United States have olfactory impairment or loss of smell, yet few treatments are available.